Key Highlights

  • Shares were down 7.76% at USD 2.14 in premarket trading on November 4, 2026.
  • Cash and investments stood at USD 344.1 million at June 30, 2026, which the company said funds operations into 2028.
  • Second quarter 2026 net loss reached USD 56.5 million, compared with USD 28.4 million a year earlier.
  • BBO-8520 posted a 63% objective response rate (26 of 41 patients) as monotherapy in an inhibitor-naive lung cancer group.
  • Combined with pembrolizumab, BBO-8520 showed a 75% response rate at 500 mg once daily.

What Moved BridgeBio Oncology Before the Open (down USD 0.1800, 7.76%)

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) fell 7.76%, or USD 0.1800, to USD 2.14 in premarket trading on November 4, 2026, measured against the November 3 close. No company press release, regulatory filing or trial update dated November 2 to November 4, 2026 was identified as a catalyst.

The decline more likely reflects continued weakness in a stock that has fallen sharply since the summer. On October 12, 2026, the company reported inducement Options priced at USD 3.31 per share, so the current price sits well below that level (calculated, about 35% lower). As a penny stock, it can swing widely on thin liquidity, and further share issuance is a standing risk for clinical-stage biotechs.

Recent Company Updates and Data

The most important recent event was the September 8, 2026 release of new Phase 1 data for BBO-8520, a KRAS G12C inhibitor. In inhibitor-naive second-line and later lung cancer, monotherapy produced a 63% objective response rate (26 of 41 patients). Among patients who had previously received a KRAS G12C inhibitor and were treated with pembrolizumab, the response rate was 75% at 500 mg once daily and 53% across all doses (17 patients).

Despite those figures, the shares fell 23.76% that day, which suggests investors were weighing cross-trial comparisons and durability questions rather than the headline response rates. Earlier, on January 7, 2026, the company had reported a 65% response rate for BBO-8520 monotherapy in KRAS G12C lung cancer.

Other pipeline Assets include BBO-10203, a first-in-class RAS and PI3K Alpha breaker, and BBO-11818, a pan-KRAS inhibitor. Updated clinical data for both were guided for the second half of 2026, with readouts expected from late 2026 through mid-2027.

Business Background

BridgeBio Oncology Therapeutics is a clinical-stage company developing small molecules aimed at RAS-driven cancers. It has no approved products and no product revenue. Pedro J. Beltran became chief executive officer effective April 20, 2026, with Neil Kumar serving as executive chairman.

Balance Sheet and Risks

Spending is rising as programs advance. In the second quarter of 2026, Research and Development expense was USD 49.2 million, against USD 27.4 million a year earlier, while general and administrative expense was USD 11.0 million, against USD 2.7 million. The net loss was USD 56.5 million, compared with USD 28.4 million.

Cash and investments fell from USD 388.9 million at March 31, 2026 to USD 344.1 million at June 30, 2026, a reduction of USD 44.8 million (calculated). The company said the balance funds operations into 2028. Key risks include trial results that disappoint, competition in KRAS targeted therapy and the possibility of future Equity raises at lower prices.

What to Watch Next

The third quarter 2026 report has not yet been identified. Prior reports came on May 12 and August 11, 2026, so a mid-November filing would fit that pattern. Investors will look at cash burn, any update on BBO-10203 and BBO-11818 data timing, and whether the stock steadies after this premarket drop.